You are here

Skeletal muscle toxicity associated with TKIs in CML patients

Up to 80% of CML patients using tyrosine kinase inhibitors (TKIs) reports muscle complaints. These muscle complaints are strongly related to the presence of fatigue and contributes to both diminished disease control and impaired quality of life. Although the mechanism by which TKIs cause muscle complaints is poorly understood, mitochondrial dysfunction has been suggested to play a pivotal role in TKI-induced cardiac muscle toxicity.

For further reading, follow the link below: